



Patent  
Office



INVESTOR IN PEOPLE

09/831290

The Patent Office  
Concept House  
Cardiff Road  
Newport

South Wales

NP10 8QQ'D 08 DEC 1999

WIPO

PCT

4


GB99/3789

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *Andrew Gurney*  
Dated 25 November 1999

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)



RECEIVED BY POST

17 NOV 98 E405022-1 D02934  
P01/7700 0.00 - 9825055.8

# Request for grant of a patent

(See notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference

PHM 98-067

2. Patent application number

(The Patent Office will fill in this part)

9825055.8

17 NOV 1998

3. Full name, address and postcode of the or of each applicant (underline all surnames)

ZENECA Limited

15 Stanhope Gate

London W1Y 6LN Great Britain

Patents ADP number (if you know it)

6254007002

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

METHOD

5. Name of your agent (if you have one)

PHILLIPS, Neil Godfrey Alasdair

"Address for service" in the United Kingdom to which all correspondence should be sent

(including the postcode)

Intellectual Property Department

ZENECA Pharmaceuticals, Mereside

Alderley Park, Macclesfield, Cheshire, SK10 4TG, Great Britain

Patents ADP number (if you know it) 6570543002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d)).

19. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 6

Claim(s)

Abstract

Drawing(s) 1 + 1

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date 16 Nov 98

Lynda M. Slack

12. Name and daytime telephone number of person to contact in the United Kingdom Telephone Dawn Beckley (01625 516485)

#### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

#### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

## Method

The present invention relates to a cell-based screen for inhibitors of fungal inositolphosphoryl-ceramide (IPC) synthase, an important antifungal target.

5 Inhibitors of fungal IPC synthase are potent and selective antifungal agents for example Aureobasidin, Khafrefungin and Rustmicin) as identified by several research groups and pharmaceutical companies.

However, all such compounds are natural products that are difficult to produce, handle and administer to a patient (for example, they may have unsuitable pharmacokinetics).

10 Therefore it is highly desirable to obtain other novel chemical compounds selectively inhibiting the same target (a fungal IPC synthase) but without the intrinsic disadvantages displayed by the currently known inhibitors. Screening for such novel chemicals as well as optimisation of already available "leads" (ie. optimisation of a known inhibitor in a structure-based design or lead optimisation) will require an assay for IPC synthase activity that can be  
15 performed at a sufficiently high throughput.

All currently available biochemical assays for IPC synthase are involved and very labour-intensive.

Nagiec et al (Journal of Biological Chemistry, Vol 272 No 15, pp 9809-9817 (1997))) describe the complementation of an IPC synthase gene defect in a mutant strain of *S. Cerevisiae* by the *AUR1* gene. The mutant strain has a deletion of the *LCB1* gene and a point  
20 mutation that creates the suppressor gene *SLC1-1*. The *lcb1* mutation prevents sphingolipid synthesis and the *SLC-1-1* gene enables the cells to make phospholipids and remain viable. (Use of capital letters implies a functional gene or a gain of function mutation such as *SLC1-1* whereas small letters indicate a non functional allele such as *lcb1*). Using this the authors  
25 were able to isolate a mutant strain defective in IPC synthase and to isolate a gene *AUR1* which complemented the IPC synthase defect and restored IPC synthase activity. The authors conclude that IPC synthase is the target for antifungal agents such as aureobasidin. They postulate that it should be possible to develop high throughput screens to identify new inhibitors of IPC synthase to combat fungal diseases.

30 However we have found that whilst a similar strain of *S. cerevisiae* (*lcb1* / *SLC1-1*) is viable, the strain grows very poorly and is extremely sensitive to any environmental

influences such as for example freezing. This strain is simply not robust enough for screening purposes.

We now provide a robust cell-based assay for identifying selective IPC synthase inhibitors. This assay is based on our development of an *S. cerevisiae* strain wherein the production of compensatory phospholipids is enhanced.

Therefore in a first aspect of the present invention we provide a screening assay for identifying a selective IPC synthase inhibitor which assay comprises contacting a test compound with engineered cells whose capability to synthesize sphingolipids depends on the addition of exogenous phytosphingosine and which are capable of sustained growth via compensatory phospholipids, adding phytosphingosine, and determining IPC synthase inhibition by the test compound by reference to any cell growth inhibition.

Any convenient host cell strain may be used provided that it can function as a host for a fungal IPC synthase gene. Convenient hosts include fungi that are manipulatable genetically such as *S. cerevisiae* but also others such as *Candida albicans*, *Candida glabrata*, *Aspergillus* sp. or *Schizosaccharomyces pombe*. Convenient sources for the AUR1 gene are pathogenic (also phytopathogenic) fungi as outlined above and others such as *Ashbya* sp., *Fusarium* sp., *Trichoderma* sp., *Cryptococci*, *Blastomyces*, and *Histoplasma*.

Whilst we do not wish to be bound by theoretical considerations the compensatory phospholipids are believed to be novel glycerophospholipids that may compensate for one or more functions of sphingolipids essential for vegetative growth (Lester et al, J.Biol.Chem., 1993, 268, 845-856).

In a further aspect of the invention we provide engineered cells whose capability to synthesize sphingolipids depends on the addition of exogenous phytosphingosine and which are capable of sustained growth via compensatory phospholipids

By "sustained growth" we mean no significant decrease of viable cell counts during a growth period (ie. cell-death is negligible compared to cell growth). The strain also has to be capable of one or more of the following: being stored for prolonged periods, for example up to three or six months or longer; storage in liquid medium; or capable of being frozen and revived. The engineered cells of the invention are capable and robust enough for routine use in high throughput assay procedures. In general they will have generation times compatible with growth assays (ie. not more than 4 hours per doubling) and final optical densities reached

of more than 4 OD (at 600 nm and 1 cm path length). These parameters allow complete assessment of a host strain's growth within less than 30 hours.

A convenient host strain for use in the assay methods of the invention is an *lcb1* / SLC1-1 strain. More conveniently it will include a selection marker, for example the *lcb1* gene may be directly replaced by an amino acid biosynthetic gene (such as LEU2, TRP1 or HIS3) or antibiotic resistance such as Geneticin (G418).

Adapting host cells for sustained growth is for example achieved by enhancing expression of the compensatory mutant SLC1-1 allele. We have surprisingly found that can be achieved by cloning the SLC1-1 gene onto a multi-copy plasmid (pYES2-LEU2d- GPD3- SLC1-1 = pNS149) under control of the glyceraldehyde 3-phosphate dehydrogenase promoter. Use of a multi-copy pGPD-SLC1-1 promoter/gene construct yielded a strain with much improved growth characteristics, improved growth rate, final optical density and resistance to freezing. In summary it provided for the first time a host strain which is robust enough for screening purposes.

The GPD3 is an example of a very strong *S. cerevisiae* promoter. Other glycolytic enzymes such as PGK, ENO, PYK FBA are convenient sources of other such promoters.

Therefore in a further aspect of the invention we provide an engineered host strain *S. cerevisiae* (*lcb1* / pGPD-SLC1-1).

The invention will now be illustrated but not limited by reference to the following specific description and Figures:

### *Construction of the IPC synthase screening strain (lcb1::kanMX, pNS149 (pGPD3-SLC1-1))*

#### 1. Generation of a *LCB1* deletion strain

As *LCB1* is an essential gene, only one allele of a diploid cell can be deleted without loss of survival. Added phytosphingosine can, however, substitute for an intact *LCB1* gene. Technically, one *LCB1* allele of a diploid *S. cerevisiae* strain (JK9-3daa - Kunz, J. et al, Cell, 1993, 73, 585-596) was disrupted using the kanamycin resistance cassette as described by Wach et al, Yeast, 1996, 12, 259-265.

PCR primers used to create the *LCB1* deletion (*lcb1::kanMX*)

5' Primer :

GCAATGGCACACATCCCAGAGGTTTTACCCAAATCAATACCGATTCCGGCATTTA

5 TTGCAGCTGAAGCTTCGTACGCTGCAG

3' Primer:

CTATTTTTATTATTAGATTCTTGGCAACAGGCAAGGATGGACTGCTTGACCCGCA

TAGGCCACTAGTGGATCTG

10 Disruption of *LCB1* and its replacement by *kanMX* was verified by PCR (using  
primers 5' of the deleted region directed towards the gene and within *kanMX* facing towards  
the promoter). Sporulation of the heterozygous diploid (*LCB1/lcb1::KanMX*) and tetrad  
dissection yields 2 kanamycin-sensitive colonies per tetrad when grown on YPD (Sherman et  
al, Methods in Yeast Genetics, 1986, Cold Spring Harbor Laboratory Press, Cold Spring  
15 Harbor N.Y. media) without phytosphingosine, however if the ascus is dissected on media  
containing 10mM phytosphingosine this results in 4 colonies per tetrad, two of which are  
resistant to kanamycin (and therefore are *lcb1::kanMX*).

## 2. Generation of a *SLC1-1* allele cloned into a multi-copy plasmid

20

The dominant *SLC1-1* allele was generated from the wildtype allele by PCR  
regenerating the sequence as described by Nagiec *et al.* (*op cit*). The mutant *SLC1-1* allele  
differs from the wildtype allele by a single nucleotide which changes Glutamine 44 in the  
wild-type protein to Leucine in the suppressor protein. According to the literature (Nagiec *et*  
25 *al, op cit*) this mutation should rescue the *lcb1::kanMX* strain, allowing growth on media  
without added phytosphingosine.

The *SLC1-1* was amplified from genomic DNA by PCR (creating the point mutation  
via a mismatch in the 5' primer) and cloned into expression plasmids (eg pYES2-Leu2  
30 (Invitrogen), modified by an inserted Leu2 selection marker = pNS144) using BamHI (5') and  
SphI (3') as insertion sites (to give pNS145). After transformation (5) into *lcb1::kanMX* (3),



(selection SGal-leucine, no phyto-sphingosine added) microcolonies were established after 12 days of incubation proving and confirming the suppressing function of SLC1-1. However, the viability of these transformants was extremely poor and they were not maintainable in liquid culture. Establishment of frozen stocks from the colonies also failed. A similar phenotype was also observed if the homologous SLC1 promoter was used instead of Gal1 (pNS148).

Primers to generate SLC1-1 by PCR. Restriction sites are shown in bold. The point mutation generating Leu 44 is shown underlined in italics

SLC1-1 5'  
CGCGGATCCATGAGTGTGATAGGTAGGTTCTTGTATTACTTGAGGTCCGTGTTGGT  
CGTACTGGCGCTTGCAGGCTGTGGCTTTTACGGTGTAATCGCCTCTATCCTGTGCA  
CGTTAATCGGTAAGCAACATTTGGCTCIGTGG

SLC1-1 3'  
ACATGCATGCTTAATGCATCTTTTTTACAGATGAACC

### 3. Generation of a GPD3-driven SLC1-1 allele

We postulated that the poor viability of the *lcb1::kanMX* pNS145 strain might be due to insufficient expression of *SLC1-1*, so increased expression was attempted. We placed the *SLC1-1* gene under control of the glyceraldehyde-3-phosphate dehydrogenase GPD3 (=TDH3), promoter (Norbeck et al, Yeast, 1997, 16, 1519-1534).

The GPD3 promoter was amplified from *S. cerevisiae* chromosomal DNA by PCR and inserted into a *HinDIII* site of pNS145 (just 5' of the SLC1-1 start ATG) to create plasmid pNS149 which is a further independent aspect of the invention.

PCR primers generating the GPD3 promoter. Restriction sites are shown in bold

PGPD5'

CCCAAGCTTGCCGGCÁCTAGTTCGAGTTTATCATTATCAATACTCGCC

pGPD 3'

GTAAGCTTTATTCGAAACTAAGTTCTTGGTG

5


Transformation (Ito *et al*, J. Bacteriology, 1983, 153, 163-168) of pNS149 into lcb1::kanMX (see 2. above) yielded readily viable colonies, that also grew very well in liquid culture and were able to recover from freeze-storage.

10 **4. The IPC synthase screen**

The utility of the lcb1::kanMX pNS149 strain to identify inhibitors of IPC synthase was evaluated using aureobasidinA as a test compound. The lcb1::kanMX pNS149 strain is a further independent aspect of the invention. As shown in Figure 1, the test compound could be  
15 readily identified, as predicted. Inhibition by aureobasidinA was very pronounced in the presence of phytosphingosine but absent if no phytosphingosine was added.

Figure 1 - Inhibition of growth by aureobasidinA in strain lcb1::kanMX, pNS149 with and without phytosphingosine added.

20

**FIGURE 1**

PCF/SW79/05107

12/11/99CP

Zeneca Pharmaceuticals